Tema Heart & Health ETF (NASDAQ:HRTS) Stock Short Interest Declines 82.2%

Tema Heart & Health ETF (NASDAQ:HRTS) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 917 shares, a decline of 82.2% from the August 31st total of 5,158 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 2,266 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Tema Heart & Health ETF

Several institutional investors and hedge funds have recently bought and sold shares of the company. Anson Capital Inc. purchased a new stake in shares of Tema Heart & Health ETF in the 2nd quarter valued at approximately $297,000. Members Advisory Group LLC purchased a new stake in shares of Tema Heart & Health ETF during the 2nd quarter valued at approximately $398,000. XML Financial LLC acquired a new position in Tema Heart & Health ETF in the second quarter valued at approximately $223,000. Rothschild Capital Partners LLC acquired a new position in Tema Heart & Health ETF in the second quarter valued at approximately $651,000. Finally, Royal Bank of Canada grew its position in Tema Heart & Health ETF by 8.8% in the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after acquiring an additional 1,703 shares during the period.

Tema Heart & Health ETF Stock Performance

NASDAQ:HRTS opened at $36.26 on Friday. Tema Heart & Health ETF has a one year low of $29.54 and a one year high of $38.87. The stock has a market cap of $53.66 million, a PE ratio of 22.06 and a beta of 0.63. The stock has a 50 day moving average price of $37.07 and a 200 day moving average price of $35.29.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.